Key result
IABP plus ivabradine enables beta-blocker titration and drives ~34-point LVEF improvement in severe HFrEF.
Why the study?
Pulsus alternans is considered a sign of poor prognosis in heart failure and may be overlooked in patients with IABPs. The use of IABP and ivabradine for beta-blocker introduction in a patient with DCM and pulsus alternans and its consequence had never been reported.
Can intra-aortic balloon pumping and ivabradine stabilize haemodynamics, eliminate pulsus alternans, and facilitate successful beta-blocker introduction and left ventricular reverse remodelling in a patient with new-onset dilated cardiomyopathy and initial beta-blocker intolerance?
Case Report (n=1)
No
Can intra-aortic balloon pumping and ivabradine stabilize haemodynamics, eliminate pulsus alternans, and facilitate successful beta-blocker introduction and left ventricular reverse remodelling in a patient with new-onset dilated cardiomyopathy and initial beta-blocker intolerance?
In patients with new-onset dilated cardiomyopathy complicated by sinus tachycardia, pulsus alternans, and beta-blocker intolerance, combined IABP and ivabradine support can resolve pulsus alternans and stabilize haemodynamics to allow successful beta-blocker initiation and subsequent left ventricular reverse remodelling.
Answers are grounded in this paper and cite their sources.
May support IABP-ivabradine bridge to enable beta-blocker titration in select intolerant DCM; hypothesis-generating and should not yet change practice.
Background: Pulsus alternans has been considered a sign of poor prognosis in patients undergoing treatments for heart failure. However, it may be overlooked in patients with intra-aortic balloon pumps (IABPs). The use of IABP and ivabradine for a β-blocker introduction in a patient with dilated cardiomyopathy (DCM) and pulsus alternans and its consequence have never been reported. Case summary: In a 16-year-old high school boy with idiopathic DCM [left ventricular end-diastolic diameter (LVDd), 72 mm; left ventricular ejection fraction (LVEF), 18%], the introduction of carvedilol therapy failed, causing cardiogenic shock under inotropes. Therefore, an IABP support was provided, and he was transferred to our hospital. The arterial pressure waveform under IABP demonstrated pulsus alternans with sinus tachycardia at 135/min. Ivabradine reduced the heart rate to ∼100/min and eliminated the pulsus alternans neither decreasing the cardiac index nor increasing the pulmonary artery wedge pressure. Subsequently, carvedilol was reintroduced, and IABP and inotropes were discontinued. Then, 112 days after his transfer to our hospital, left ventricular reverse remodelling was confirmed (LVDd, 54 mm; LVEF, 44%), and he returned to school. The carvedilol dose reached 20 mg/day in 4 months after discharge, and further improvement was observed a year after discharge (LVDd, 54 mm; LVEF, 52%). Discussion: Pulsus alternans is considered a predictor of poor prognosis. However, IABP and ivabradine may stabilize the haemodynamics in pulsus alternans, leading to a successful β-blocker introduction.
No takes yet. Share an insight, caveat, or question.
Kashimura et al. (2023) conducted a case report in New-onset idiopathic dilated cardiomyopathy with sinus tachycardia and pulsus alternans (n=1). Intra-aortic balloon pumping (IABP) and ivabradine facilitating carvedilol introduction was evaluated on Elimination of pulsus alternans, successful beta-blocker introduction, and left ventricular reverse remodelling (LVEF and LVDd). IABP and ivabradine reduced heart rate from 135 to ~100/min and eliminated pulsus alternans, enabling carvedilol titration and improving LVEF from 18% to 52% at 1 year.
Synapse has enriched 10 related papers. Consider them for comparative context: